Admin_Adham
April 8 (Reuters) - Lab equipment maker Waters said on Wednesday the U.S. Food and Drug Administration has cleared its at-home cervical cancer screening kit for use with an approved HPV test, potentially improving early detection and reducing deaths from the cancer.
Shares of the company were up about 4% in early trading.
- Waters said about 60% of cervical cancers occur in peoplewho are not screened or are screened less often thanrecommended.
- The self-collection kit, tested with BD's Onclarity HPVassay, is designed to detect all high-risk types of humanpapillomavirus, Waters added.
- Patients can collect a sample at home and mail it to alaboratory, with results shared with their healthcare provider,the company said.
- The World Health Organization estimates that persistentHPV infection of the cervix, if untreated, causes around 95% ofcervical cancers.
- The company said it worked with the U.S. National CancerInstitute to confirm the accuracy of home sample collection.
- Waters said it is setting up partnerships to make the kitavailable nationwide by prescription in the coming months.
- The company said the kit is expected to be covered byprivate insurance as well as federal programs such as Medicareand Medicaid.
(Reporting by Sahil Pandey in Bengaluru; Editing by Vijay Kishore)
